Endoscopic Remission News Today

Results presented in a paper at ACG 2023 showed upadacitinib was more effective than ustekinumab for achieving clinical response and endoscopic remission.

Announced by AbbVie on October 15, 2023, positive results revealed 59% of patients treated with risankizumab and 40% of patients treated with ustekinumab achieved clinical remission, respectively.

RVT-3101 demonstrated improved efficacy results from the induction to chronic period in the TUSCANY-2 Phase 2b study in ulcerative colitis and was well...

RVT-3101 demonstrated improved efficacy results from the induction to chronic period in the TUSCANY-2 Phase 2b study in ulcerative colitis and was well tolerated with a favorable safety profile across all dosesA Phase 2 study of RVT-3101 in Crohn’s ...

This is the first-ever long-duration data reported for an anti-TL1A antibodyAt the expected Phase 3 once-monthly subcutaneous dose in the overall population, RVT-3101 treatment resulted in improved Clinical Remission1 (36% at week 56 vs. 29% at week 14) a...

A total of 24 accepted abstracts, including six oral and digital oral presentations, reinforce AbbVies commitment to research that helps advance standards of...

/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced it would present new data across its rheumatology portfolio, including RINVOQ® (upadacitinib) for...

Thirty-six abstracts underscore AbbVies commitment to advancing research to help more people living with rheumatic diseasesAdditional analysis of...

RINVOQ is now approved as the first and only oral JAK inhibitor for adults with active non-radiographic axial spondyloarthritis (nr-axSpA)RINVOQ i...

/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced The Lancet published results from three pivotal Phase 3 clinical trials – U-ACHIEVE (induction),...